The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
==== MeSH D12.776.467.374.400 – growth substances ==== MeSH D12.776.467.374.400.442 – hematopoietic cell growth factors MeSH D12.776.467.374.400.442.240 – colony-stimulating factors MeSH D12.776.467.374.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.075.350.275 – filgrastim MeSH D12.776.467.374.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.150 – erythropoietin MeSH D12.776.467.374.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.776.467.374.400.442.240.150.250.250 – epoetin alfa MeSH D12.776.467.374.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.776.467.374.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.350.375.275 – filgrastim MeSH D12.776.467.374.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.400 – interleukin-3 MeSH D12.776.467.374.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.750 – thrombopoietin MeSH D12.776.467.374.400.442.800 – stem cell factor MeSH D12.776.467.374.400.505 – interleukins MeSH D12.776.467.374.400.505.501 – interleukin-1 MeSH D12.776.467.374.400.505.502 – interleukin-2 MeSH D12.776.467.374.400.505.503 – interleukin-3 MeSH D12.776.467.374.400.505.504 – interleukin-4 MeSH D12.776.467.374.400.505.505 – interleukin-5 MeSH D12.776.467.374.400.505.506 – interleukin-6 MeSH D12.776.467.374.400.505.507 – interleukin-7 MeSH D12.776.467.374.400.505.508 – interleukin-8 MeSH D12.776.467.374.400.505.509 – interleukin-9 MeSH D12.776.467.374.400.505.510 – interleukin-10 MeSH D12.776.467.374.400.505.511 – interleukin-11 MeSH D12.776.467.374.400.505.512 – interleukin-12 MeSH D12.776.467.374.400.505.513 – interleukin-13 MeSH D12.776.467.374.400.505.514 – interleukin-14 MeSH D12.776.467.374.400.505.515 – interleukin-15 MeSH D12.776.467.374.400.505.516 – interleukin-16 MeSH D12.776.467.374.400.505.517 – interleukin-17 MeSH D12.776.467.374.400.505.518 – interleukin-18 MeSH D12.776.467.374.400.800 – transforming growth factor beta
A single dose of LSD (Definium Therapeutics's DT120 candidate) markedly reduced major depressive disorder symptoms versus placebo in a Phase 3 trial, with benefits lasting at least 12 weeks and no major safety concerns. LSD is a psychoplastogen, a compound capable of promoting rapid and sustained neural plasticity, an action that hypothetically might be involved in its therapeutic benefits. Preliminary evidence in humans suggests that a single dose of LSD may also temporarily benefit learning and memory. More research is needed to substantiate such notions. The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of psychedelics like LSD for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.
Generation of Neutralizing Human Monoclonal Antibodies Against a Therapeutic Target from the Alloy Therapeutics Mouse Generation Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms Development of Antibody and PK, and ADA Assays for a Cystine Knot Fusion Protein A Rapid, High-Throughput Recombinant Antibody Expression System for Therapeutic Antibody Discovery and Validation Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse Generation and Selection of Human Monoclonal Antibodies from the OmniRat Therapeutic Antibody Discovery at Antibody Solutions using the OmniAb Platform Development of human antibodies to human vascular endothelial growth factor -C (VEGF-C) and -D (VEGF-D) Obtaining Antibodies to Difficult Membrane Targets through DNA and Cell Immunization Next-Generation Therapeutic Antibody Discovery from Single B-cells Generation and Selection of Human Monoclonal Antibodies from the H2L2 Mouse Generation of Antibodies to Difficult Membrane Protein Targets Development of Antibodies and ELISAs to measure Free and Total Obiltoxaximab (ETI-204) in the Presence of Anthrax Protective Antigen PA63 Discovery of Therapeutic Antibodies to Difficult Membrane Proteins
=== Pharmacokinetics === The half-life of venlafaxine is about 5 hours, and with once-daily dosing, steady-state concentration is achieved after about 3 days, though its active metabolite desvenlafaxine lasts longer. The half-life of desvenlafaxine is about 11 hours, and steady-state concentrations are achieved after 4 to 5 days. The half-life of duloxetine is about 12 hours (range: 8–17 hours), and steady-state is achieved after about 3 days. Milnacipran has a half-life of about 6 to 8 hours, and steady-state levels are reached within 36 to 48 hours.
Sources: en.wikipedia.org
The rapid expansion of AI infrastructure has significant environmental implications. The energy demands of data centres are projected to grow substantially, potentially conflicting with the UK's net-zero targets and straining grid capacity. Additionally, the water consumption required for cooling data centres has raised sustainability concerns. Beyond domestic impacts, the global AI supply chain relies heavily on the extraction of critical minerals (such as cobalt and lithium) in the Global South, often associated with environmental degradation and human rights abuses. The development of AI models also depends on low-wage "ghost workers" in developing nations for data annotation and content moderation, prompting calls for mandatory human rights due diligence laws. While economic forecasts suggest AI could significantly boost UK GDP and productivity, realising these gains faces a "productivity paradox". Despite experimental evidence of productivity improvements, economy-wide data does not yet reflect an AI-driven boost, largely due to low adoption rates of bespoke systems among traditional businesses and the concentration of economic value among a small percentage of organisations. Furthermore, economists warn of "algorithmic rents", where dominant tech platforms extract wealth, potentially eroding the UK tax base and exacerbating market concentration. The UK's Digital Services Tax (DST) attempts to address this but remains controversial with the US government.
==== Peripheral nervous system ==== Eight to ten nerves arise from the cerebral ganglia to supply the prostomium, buccal chamber and pharynx. Three pairs of nerves arise from the subpharyngeal ganglia to supply the second, third and fourth segment. Three pairs of nerves extend from each segmental ganglion to supply various structures of the segment. The sympathetic nervous system consists of nerve plexuses in the epidermis and alimentary canal. The nerves that run along the body wall pass between the outer circular and inner longitudinal muscle layers of the wall. They give off branches that form the intermuscular plexus and the subepidermal plexus. These nerves connect with the cricopharyngeal connective.
The underlying principle of COLD-PCR is that single nucleotide mismatches will slightly alter the melting temperature (Tm) of the double-stranded DNA. Depending on the sequence context and position of the mismatch, Tm changes of 0.2–1.5 °C (0.36–2.7 °F) are common for sequences up to 200bp or higher. Knowing this the authors of the protocol took advantage of two observations:
Trump further announced that month a plan for a new fleet of naval vessels, to be called Trump-class battleships, although battleships have long been obsolete in naval warfare and the Navy's last one in service was decommissioned in 1992. For many years, the National Park Service's annual general pass depicted natural landscapes, but the new 2026 pass design for U.S. residents has a photo of Donald Trump. The redesign triggered a popular backlash of passholders' covering his photo with stickers; the Park Service responded by updating its ban on defaced passes to include anything obscuring the front. The year also marked the Treasury's announcement that Trump's own signature would replace that of the treasurer on paper currency, another first for a president; the State Department’s issuance of a new passport design with a portrait of Trump, the first living president to appear on a U.S. passport, offered as an option to in-person applicants at the Washington, D.C., Passport Agency; and Florida Gov. Ron DeSantis's consent to renaming Palm Beach International Airport after Trump, a change the president had reportedly sought in 2020. Other measures bearing Trump’s name are Trump accounts, tax-advantaged investment accounts for American minors rolled out as part of the One Big Beautiful Bill Act; TrumpRx, a prescription drug website run by the federal government; and the Trump Gold Card, a program offering foreign nationals expedited U.S. residency in exchange for donations of $1 million or more to the Commerce Department and denounced by U.S. Sen.
==== Inflammation and allergy ==== 12-HHT stimulates chemotactic responses in mouse bone marrow mast cells, which naturally express BLT2 receptors, as well as in Chinese hamster ovary cells made to express these receptors by transfection. These findings suggest that the 12-HHT/BLT2 receptor pathway may support the pro-inflammatory (i.e. chemotactic) actions of the LTB4/BLT1 pathway. On the other hand, the immortalized human skin cell line HaCaT expresses BLT2 receptors and responds to ultraviolet B (UVB) radiation by generating toxic reactive oxygen species which in turn cause the HaCaT cells to die by activating apoptotic pathways in a BLT2 receptor-dependent reaction. Topical treatment of mouse skin with a BLT2 receptor antagonist, LY255283, protects against UVB radiation-induced apoptosis and BLT2-overexpressing transgenic mice exhibited significantly more extensive skin apoptosis in response to UVB irradiation. Furthermore, 12-HHT inhibits HaCaT cells from synthesizing interleukin-6 (IL-6), a pro-inflammatory cytokine associated with cutaneous inflammation, in response to UVB radiation. These results suggest that the 12-HHT/BLT2 axis can act to suppress inflammation by promoting the orderly death of damaged cells and blocking IL-6 production. Opposition between the pro-inflammatory LTB4/BLT1 and anti-inflammatory actions of the 12-HHT/BLT2 axes occurs in another setting.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.